{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:45:23Z","timestamp":1778964323035,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.vaccine.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T10:48:59Z","timestamp":1519987739000},"page":"1908-1916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study"],"prefix":"10.1016","volume":"36","author":[{"given":"Clare L.","family":"Cutland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Kurugol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khatija","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten P.","family":"Perrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen S","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Ceyhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devayani","family":"Kolhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Hezareh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van Der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.02.013_b0005","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martinon-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.02.013_b0010","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(12)61187-8","article-title":"Effect of vaccines on bacterial meningitis worldwide","volume":"380","author":"McIntyre","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.02.013_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2018.02.013_b0020","first-page":"21","article-title":"Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016","volume":"2016","author":"Campbell","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.02.013_b0025","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jinf.2015.07.007","article-title":"Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage","volume":"71","author":"Lucidarme","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.02.013_b0030","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","article-title":"Global epidemiology of capsular group W meningococcal disease (1970\u20132015): Multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex","volume":"34","author":"Mustapha","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0035","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3201\/eid2210.151935","article-title":"Increase in meningococcal serogroup W disease, Victoria, Australia, 2013\u20132015","volume":"22","author":"Carville","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.013_b0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erv.10.3","article-title":"The epidemiology of meningococcal disease and the impact of vaccines","volume":"9","author":"Khatami","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.02.013_b0045","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.02.013_b0050","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): A review of its immunogenicity, safety, co-administration, and antibody persistence","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.013_b0055","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/INF.0000000000001484","article-title":"Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants: an open, randomized trial","volume":"36","author":"Merino Arribas","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.013_b0060","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.013_b0065","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0070","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0075","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.013_b0080","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0085","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","article-title":"Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children","volume":"35","author":"Klein","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.013_b0090","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4161\/hv.20229","article-title":"Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children","volume":"8","author":"Knuf","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.013_b0095","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.013_b0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.013_b0105","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.013_b0110","unstructured":"European Medicines Agency. Prevenar 13. Summary of product characteristics. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001104\/WC500057247.pdf> [accessed 2017 February 7]."},{"key":"10.1016\/j.vaccine.2018.02.013_b0115","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.02.013_b0120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/CDLI.8.2.266-272.2001","article-title":"Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay","volume":"8","author":"Concepcion","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.02.013_b0125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CDLI.4.4.415-422.1997","article-title":"Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells","volume":"4","author":"Romero-Steiner","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.02.013_b0130","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.02.013_b0135","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection-serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0140","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2016.05.009","article-title":"Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers","volume":"34","author":"Bona","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0145","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.02.013_b0150","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10096-009-0848-8","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers","volume":"29","author":"Halperin","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.013_b0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2014.03.1390","article-title":"Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers","volume":"26","author":"Tregnaghi","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.013_b0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/INF.0b013e3182784143","volume":"32","author":"Ruiz-Palacios","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.02.013_b0165","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0170","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.vaccine.2014.08.027","article-title":"Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C\/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy","volume":"33","author":"Leonardi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.013_b0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40272-013-0047-z","article-title":"13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents","volume":"15","author":"Plosker","year":"2013","journal-title":"Paediatr Drugs"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T22:42:55Z","timestamp":1603924975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18301877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0264410X18301877"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}